Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Boon Piang CherSharon GohMohamed Ismail Abdul AzizGrace WongRaymond Ng Chee HuiBenjamin Shao-Kiat OngKwong-Hoe NgPublished in: Expert review of pharmacoeconomics & outcomes research (2023)
At its current price, sacituzumab govitecan does not represent a cost-effective treatment for relapsed or refractory metastatic TNBC in Singapore. Our findings will be useful to inform funding decisions alongside other factors including clinical effectiveness, safety, and budget impact considerations.